Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators
Authors
Keywords
-
Journal
ChemMedChem
Volume 11, Issue 5, Pages 450-466
Publisher
Wiley
Online
2016-02-03
DOI
10.1002/cmdc.201500566
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Blocking of the PD-1/PD-L1 Interaction by aD-Peptide Antagonist for Cancer Immunotherapy
- (2015) Hao-Nan Chang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Immunotherapeutic Impact of Toll-like Receptor Agonists in Breast Cancer
- (2015) Christine Zhang et al. Anti-Cancer Agents in Medicinal Chemistry
- Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity
- (2015) Adam J. R. Gadd et al. BIOCONJUGATE CHEMISTRY
- Cytosolic sensing of aberrant DNA: arming STING on the endoplasmic reticulum
- (2015) Qiang Wang et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Therapeutic targeting of Toll-like receptors in cutaneous disorders
- (2015) Nassim Matin et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment
- (2015) Johanna M Gostner et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Research progress of indoleamine 2,3-dioxygenase inhibitors
- (2015) Tianze Jiang et al. Future Medicinal Chemistry
- Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening
- (2015) Jian-Sung Wu et al. JOURNAL OF MEDICINAL CHEMISTRY
- α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5′-Nucleotidase (CD73) Inhibitors
- (2015) Sanjay Bhattarai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway
- (2015) Amy B. Dounay et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity
- (2015) Mallesh Beesu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
- (2015) Ute F. Röhrig et al. JOURNAL OF MEDICINAL CHEMISTRY
- IDO inhibitors move center stage in immuno-oncology
- (2015) Cormac Sheridan NATURE BIOTECHNOLOGY
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- Big opportunities for small molecules in immuno-oncology
- (2015) Jerry L. Adams et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting the TGFβ pathway for cancer therapy
- (2015) Cindy Neuzillet et al. PHARMACOLOGY & THERAPEUTICS
- Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
- (2015) Krzysztof M. Zak et al. STRUCTURE
- New immunotherapies targeting the PD-1 pathway
- (2015) Jordan M. Chinai et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Inhibitors of the PD-1/PD-L1 Pathway Can Mobilize the Immune System: An Innovative Potential Therapy for Cancer and Chronic Infections
- (2015) Ahmed F. Abdel-Magid ACS Medicinal Chemistry Letters
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
- (2015) Leticia Corrales et al. Cell Reports
- Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
- (2015) Paul A. Beavis et al. Cancer Immunology Research
- Targeting STING pathways for the treatment of cancer
- (2015) Claudia Gravekamp et al. OncoImmunology
- A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
- (2015) Robert D. Leone et al. Computational and Structural Biotechnology Journal
- Directing the Immune System with Chemical Compounds
- (2014) Rock J. Mancini et al. ACS Chemical Biology
- Programmed Death-1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy
- (2014) Alexander Dömling et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma
- (2014) D. W. Northfelt et al. CLINICAL CANCER RESEARCH
- First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma
- (2014) Jordi Rodon et al. CLINICAL CANCER RESEARCH
- Towards Next Generation Adenosine A2A Receptor Antagonists
- (2014) G. Yuan et al. CURRENT MEDICINAL CHEMISTRY
- TGF-beta Signaling in Cancer Treatment
- (2014) Isabel Fabregat et al. CURRENT PHARMACEUTICAL DESIGN
- Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
- (2014) Ute F. Röhrig et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Adenosine pathway and cancer: where do we go from here?
- (2014) Luca Antonioli et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Immunoregulatory activity of adenosine and its role in human cancer progression
- (2014) Sylvia Muller-Haegele et al. Expert Review of Clinical Immunology
- Discovery of N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-β Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent
- (2014) Cheng Hua Jin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chemically Synthesized Molecules with the Targeting and Effector Functions of Antibodies
- (2014) Patrick J. McEnaney et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Adenosine A2B receptor antagonist PSB603 suppresses tumor growth and metastasis by inhibiting induction of regulatory T cells
- (2014) Wakako Kaji et al. JOURNAL OF TOXICOLOGICAL SCIENCES
- Genentech dives deeper into the next wave of cancer immunotherapies
- (2014) Sarah Crunkhorn NATURE REVIEWS DRUG DISCOVERY
- Crystal Structures and Structure–Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors
- (2014) Shingo Tojo et al. ACS Medicinal Chemistry Letters
- Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
- (2014) A. Young et al. Cancer Discovery
- Hostile, Hypoxia-A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists
- (2014) M. V. Sitkovsky et al. Cancer Immunology Research
- Co-blockade of immune checkpoints and adenosine A2Areceptor suppresses metastasis
- (2014) Arabella Young et al. OncoImmunology
- A Phase I study of NLG919 for adult patients with recurrent advanced solid tumors
- (2014) Asha Nayak et al. Journal for ImmunoTherapy of Cancer
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Immune Modulation in Cancer with Antibodies
- (2013) David B. Page et al. Annual Review of Medicine
- Using macrophage activation to augment immunotherapy of established tumours
- (2013) Z G Fridlender et al. BRITISH JOURNAL OF CANCER
- Toll-like receptors as therapeutic targets for cancer
- (2013) Johanna Holldack DRUG DISCOVERY TODAY
- Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes
- (2013) Jeong-Hwan Yoon et al. EMBO Molecular Medicine
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
- (2013) Li Shi et al. Journal of Hematology & Oncology
- The Yin and Yang of Toll-like receptors in cancer
- (2013) J-P Pradere et al. ONCOGENE
- Blockade of A2Areceptors potently suppresses the metastasis of CD73+tumors
- (2013) Paul A. Beavis et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular signatures of T-cell inhibition in HIV-1 infection
- (2013) Marie Larsson et al. Retrovirology
- Targeting Toll-Like Receptors: Promising Therapeutic Strategies for the Management of Sepsis-Associated Pathology and Infectious Diseases
- (2013) Athina Savva et al. Frontiers in Immunology
- A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events
- (2013) Pottayil Sasikumar et al. Journal for ImmunoTherapy of Cancer
- Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2
- (2012) Supun M. Bakmiwewa et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma
- (2012) S. J. Dovedi et al. BLOOD
- Abstract 2850: Demonstration of anti-tumor efficacy in multiple preclinical cancer models using a novel peptide inhibitor (Aurigene-012) of the PD1 signaling pathway
- (2012) Pottayil G. Sasikumar et al. CANCER RESEARCH
- Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models
- (2012) P Vandenabeele et al. CELL DEATH AND DIFFERENTIATION
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- New developments in Toll-like receptor targeted therapeutics
- (2012) Dympna J Connolly et al. CURRENT OPINION IN PHARMACOLOGY
- Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition
- (2012) Ute F. Röhrig et al. JOURNAL OF MEDICINAL CHEMISTRY
- Kynurenines in the CNS: recent advances and new questions
- (2012) László Vécsei et al. NATURE REVIEWS DRUG DISCOVERY
- Crystal structures of STING protein reveal basis for recognition of cyclic di-GMP
- (2012) Guijun Shang et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- ENTPD1/CD39 is a promising therapeutic target in oncology
- (2012) J Bastid et al. ONCOGENE
- Influence of Tryptophan Contained in 1-Methyl-Tryptophan on Antimicrobial and Immunoregulatory Functions of Indoleamine 2,3-Dioxygenase
- (2012) Silvia K. Schmidt et al. PLoS One
- Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
- (2012) L. Pilotte et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Raising the Bar: The Curative Potential of Human Cancer Immunotherapy
- (2012) S. A. Rosenberg Science Translational Medicine
- Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors
- (2011) David Meininger et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
- (2011) Primo N. Lara et al. JOURNAL OF CLINICAL ONCOLOGY
- Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators
- (2011) Eduard Dolušić et al. JOURNAL OF MEDICINAL CHEMISTRY
- The kynurenine system and immunoregulation
- (2011) Yvette Mándi et al. JOURNAL OF NEURAL TRANSMISSION
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
- (2011) Christiane A. Opitz et al. NATURE
- The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
- (2011) Christiane A. Opitz et al. PLoS One
- Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors
- (2011) Mark J. Anderton et al. TOXICOLOGIC PATHOLOGY
- Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
- (2010) X. Liu et al. BLOOD
- Toll-like receptor agonists in cancer therapy
- (2009) Sylvia Adams Immunotherapy
- Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists
- (2009) Svetlana Hamm et al. Journal of Immunotoxicology
- 1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: Development and Characterization of Adenosine A2BReceptor Antagonists and a New Radioligand with Subnanomolar Affinity and Subtype Specificity
- (2009) Thomas Borrmann et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model
- (2009) Eddy W. Yue et al. JOURNAL OF MEDICINAL CHEMISTRY
- Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer
- (2009) L. A. J. O'Neill et al. PHARMACOLOGICAL REVIEWS
- Synthesis and immunostimulatory properties of the phosphorothioate analogues of cdiGMP
- (2008) Hongbin Yan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Twelve immunotherapy drugs that could cure cancers
- (2008) Martin A. ‘Mac’ Cheever IMMUNOLOGICAL REVIEWS
- Identification of RIP1 kinase as a specific cellular target of necrostatins
- (2008) Alexei Degterev et al. Nature Chemical Biology
- Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek
- (2008) G. J. Freeman PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
- (2008) E. Lazar-Molnar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
- (2008) M. Marzec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started